The Complete Approval Roadmap
Getting a drug from Phase 3 trials to pharmacy shelves involves several distinct stages. Here is exactly where retatrutide stands in that process and what comes next.
Phase 1 — First-in-Human Safety Studies
Eli Lilly confirmed retatrutide's safety and pharmacokinetic profile in healthy volunteers. Tolerability confirmed, dose ranges established. No major safety signals identified.
Phase 2 — TRIUMPH Phase 2 Trial Published in NEJM
338 adults with obesity randomized to retatrutide or placebo over 48 weeks. Results: 24.2% mean body weight loss at 12mg — the highest ever recorded for a weight loss drug at the time. Published in the New England Journal of Medicine, July 2023.
TRIUMPH-4 — First Phase 3 Readout
445 adults with obesity and knee osteoarthritis. Results: 28.7% mean body weight loss at 68 weeks — the highest ever recorded in any Phase 3 obesity trial. Met all primary and secondary endpoints. A new safety signal — dysesthesia — emerged in 8.8% (9mg) and 20.9% (12mg) of patients. Generally mild and rarely led to discontinuation.
TRANSCEND-T2D-1 — Phase 3 Type 2 Diabetes Trial: Positive Results
537 adults with T2D (mean HbA1C 7.9%, BMI 35.8). Results: −2.0% HbA1C reduction at 9mg and 36.6 lbs (16.8%) weight loss at 12mg — with no plateau at 40 weeks. All primary and secondary endpoints met. Full TRANSCEND-T2D-1 breakdown →
6 Remaining TRIUMPH Phase 3 Trials — Readouts Expected Throughout 2026
TRIUMPH-1 (obesity, ~2,300 patients), TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (cardiovascular outcomes), TRIUMPH-5 (MASH/liver disease), TRIUMPH-6 (sleep apnea), TRIUMPH-7 (heart failure), plus a maintenance dose trial. All expected to read out in 2026. Eli Lilly needs the full data package before filing.
New Drug Application (NDA) Filing with the FDA
Once the full Phase 3 data package is compiled and analyzed, Eli Lilly will submit a New Drug Application to the FDA. This is the formal request for approval. The NDA includes all clinical trial data, manufacturing details, and proposed labeling. No official filing date has been announced by Lilly.
FDA Review — Standard or Priority Review
Standard FDA review takes 10–12 months. Priority Review (granted for drugs addressing unmet medical needs) takes 6 months. Given retatrutide's exceptional efficacy data and the public health urgency around obesity, Priority Review is considered likely by analysts — which could accelerate the timeline significantly. FDA may also convene an advisory committee.
FDA Approval Decision
If Phase 3 data is strong across all trials and the dysesthesia signal is deemed manageable, the FDA issues an approval. Retatrutide would initially be approved for one or more indications — likely obesity and/or type 2 diabetes first, with other indications following.
Commercial Launch & Pharmacy Availability
Manufacturing scale-up, distribution logistics, and insurance formulary negotiations typically add 3–6 months after approval before a drug is widely accessible. Broad insurance coverage may lag by 12–24 months after launch, as was the case with tirzepatide.
Best, Base, and Delayed Scenarios
Best Case
All TRIUMPH trials read out positively by mid-2026. NDA filed Q3 2026. FDA grants Priority Review (6 months). Approval Q1–Q2 2027. Commercial launch mid-2027.
Most Likely
TRIUMPH trials complete by late 2026. NDA filed Q4 2026 or Q1 2027. Standard 10-month FDA review. Approval mid-to-late 2027. Broad pharmacy access early 2028.
Delayed Scenario
Dysesthesia signal requires additional characterization. FDA requests supplemental safety data or cardiovascular outcomes trial. Approval slips to 2028 or beyond.
What the Prediction Markets Are Saying
Updated April 2026: Polymarket has moved from 18% to 27% approval odds in just one month — a 50% increase in implied probability. The April 3, 2026 TRANSCEND-T2D-1 Phase 3 diabetes trial results (positive on all endpoints) and continued TRIUMPH program progress are driving growing market confidence. The market still strongly favors 2027 as the more likely approval year, but the rapid upward movement is notable. Total market volume: $543,852 with real money behind these odds.
The Dysesthesia Question
The most significant variable in retatrutide's timeline is the dysesthesia safety signal that emerged in TRIUMPH-4. Dysesthesia — an abnormal sense of touch where normal sensations feel unusual or sometimes painful — was reported in 8.8% of patients at 9mg and 20.9% at 12mg, compared to just 0.7% in the placebo group.
This was not seen in Phase 2, making it a notable new finding. Eli Lilly noted it was generally mild and rarely led to treatment discontinuation. Analysts are watching closely for whether this signal appears in subsequent TRIUMPH readouts and at what severity. A few key factors:
First, the 12mg dose showing 20.9% is high in absolute terms, but most cases were mild. Second, the FDA will evaluate whether the benefit-risk profile still favors approval — given 28.7% weight loss, the bar for tolerating a mild neurological side effect is different than for a drug with modest efficacy. Third, Lilly may pursue approval at 9mg first where dysesthesia is lower, with the 12mg dose following later.
How Does FDA Review Work?
For readers unfamiliar with the process, here is what happens after Eli Lilly files the NDA:
What Approval Will Mean for Pricing & Access
Based on tirzepatide's trajectory, here is what to expect when retatrutide is approved:
List price will likely be $1,000–$1,500/month — consistent with other GLP-1 class drugs. Eli Lilly has shown willingness to offer cash-pay programs (as with Zepbound's LillyDirect platform) that reduce out-of-pocket costs significantly.
Insurance coverage will be inconsistent initially. Diabetes indications typically get covered faster than obesity indications. Many commercial plans and Medicare Part D have historically limited obesity drug coverage. This is slowly improving with advocacy and policy changes.
Availability will likely start through specialty clinics and obesity medicine practices, expanding to general practitioners over 12–18 months as the drug becomes more widely stocked.